Actineer Achieves Milestone in Actinium-225 Production
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has reached a significant milestone by successfully producing Actinium-225 (Ac-225) through the irradiation of Radium-226 (Ra-226) in a cyclotron. This accomplishment sets the stage for the joint venture to offer GMP-grade Ac-225 to healthcare providers by the middle of 2025, alongside the development of a US Drug Master File (DMF).
Importance of Actinium-225 in Cancer Treatment
Actinium-225 is increasingly recognized as a key element in developing innovative cancer therapies. It plays a critical role in drug research and clinical trials, particularly in Targeted Alpha Therapy (TAT). In this therapeutic approach, Ac-225 is combined with specific molecules that target and attach to cancer cells. Once delivered to the tumor site, Ac-225 can effectively attack cancerous cells while causing minimal damage to surrounding healthy tissues. Future therapies utilizing Ac-225 could provide powerful options for accurately targeting and eliminating cancer with fewer side effects.
Leadership Insights on Cancer Treatment Advancements
Dr. Andrew Cavey, CEO of ITM and Chairman of the Actineer Board, expressed enthusiasm about the potential of Actinium-225, stating, "This isotope represents a transformative opportunity in cancer therapy. The demand for Ac-225 is expected to surge, driven by the pressing need for novel treatments that can tackle challenging tumors and metastases. Actineer is committed to establishing a dependable and scalable supply of Ac-225, crucial for advancing clinical trials and ensuring that life-saving treatments reach patients across the globe."
Advantages of Alpha Emitters in Targeted Therapy
Alpha emitters, including Ac-225, are known for their ability to emit high-energy alpha particles that effectively penetrate cancer cells. This property allows for precise targeting of tumors, making them a powerful option for cancer treatment. Preclinical studies involving TATs with Ac-225 have demonstrated promising outcomes, revealing the isotope's effectiveness in disrupting the DNA of cancer cells, leading to their destruction.
Future Directions for Actineer and Ac-225 Production
Actineer is dedicated to enhancing its manufacturing capabilities to increase the supply of Ac-225. This approach aims to ensure that patients worldwide can benefit from this vital isotope, which could serve as a cornerstone for the next generation of cancer therapies. The joint venture's commitment to production and supply chain collaboration highlights its determination to fulfill the growing demand for Ac-225.
About Actineer, Inc.
Actineer™ Inc. is a joint venture established between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM). This partnership is focused on advancing Ac-225 technologies, securing rapid supply, and producing large-scale quantities of this essential medical radioisotope for cancer treatment. Founded recently, Actineer aims to meet the global production needs for Ac-225, recognizing the significant opportunities this isotope presents in battling cancer. The initiative also includes plans for a new Actinium Production Facility (APF) in Canada to enhance production capabilities and foster innovation within the industry.
Frequently Asked Questions
What is Actineer?
Actineer is a joint venture between ITM and Canadian Nuclear Laboratories focused on producing Actinium-225, a vital isotope for cancer treatment.
Why is Actinium-225 important?
Actinium-225 is crucial in developing targeted cancer therapies due to its ability to effectively target and destroy cancer cells while minimizing damage to healthy tissue.
When will Actineer begin supplying GMP-grade Ac-225?
Actineer aims to start supplying GMP-grade Actinium-225 by mid-2025.
What are the benefits of Targeted Alpha Therapy?
Targeted Alpha Therapy uses isotopes like Ac-225 to specifically target cancer cells, leading to effective treatment with reduced side effects compared to traditional therapies.
What are the future plans for Actineer?
Actineer plans to expand its manufacturing capabilities and work towards establishing a new Actinium Production Facility in Canada to meet the growing demand for Ac-225.
